Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
It is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and...
Saved in:
Main Authors: | Nicoletta Riva, Walter Ageno, Daniela Poli, Sophie Testa, Serena Rupoli, Rita Santoro, Teresa Lerede, Antonietta Piana, Monica Carpenedo, Alberto Nicolini, Piera Maria Ferrini, Giuliana Martini, Catello Mangione, Laura Contino, Carlo Bonfanti, Paolo Gresele, Alberto Tosetto |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2015/620217 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Splanchnic Vein Thrombosis: Etiology, Diagnosis, and Treatment
by: Xingshun Qi, et al.
Published: (2015-01-01) -
Sickle Cell Trait Causing Splanchnic Venous Thrombosis
by: Priyanka Saxena, et al.
Published: (2015-01-01) -
Systemic Venous Inflow to the Liver Allograft to Overcome Diffuse Splanchnic Venous Thrombosis
by: Cristian Lupascu, et al.
Published: (2015-01-01) -
Prevalence of Splanchnic Vein Thrombosis in Pancreatitis: A Systematic Review and Meta-Analysis of Observational Studies
by: Wenda Xu, et al.
Published: (2015-01-01) -
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
by: Salvatrice Mancuso, et al.
Published: (2020-01-01)